Sienna Biopharmaceuticals SNNAQ · USD

Its shares trade under the ticker SNNAQ. It has been listed since 27 July 2017.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. The company is headquartered in Westlake Village, California. The company went IPO on 2017-07-27. The firm is focused on developing multi-asset pipeline of topical therapies that enhance the health, appearance of life of dermatology patients. The company also advancing multiple product candidates derived from Topical by Design platform, all of which are designed to be suitable for chronic administration in patients with inflammatory skin diseases and other dermatologic and aesthetic conditions. It's SNA-120 is a first-in-class inhibitor of Tropomyosin receptor kinase A, or TrkA, in Phase IIb clinical development for the treatment of pruritus, or itch, associated with psoriasis, as well as for psoriasis itself. It's SNA-125 is a topical Janus kinase 3 (JAK3)/TrkA inhibitor with the potential to treat various inflammatory conditions, including atopic dermatitis, psoriasis and pruritus. Nonclinical studies have demonstrated anti-inflammatory activity in an animal model, and a favorable safety profile.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Keith LeonardChairman of the Board, since 2016$171,719
• Dr. Frederick BeddingfieldPresident, Chief Executive Officer, Director$2.6m
• Mr. Alexander AzoyChief Financial Officer
• Mr. Sean AndrewsVice President, Investor Relations
• Mr. Timothy AndrewsGeneral Counsel, Corporate Secretary$1.0m
• Ms. Kristina BurowDirector$137,969
• Dr. Dennis FentonDirector$147,969
• Dr. Todd HarrisDirector, since 2016$264,514
• Mr. James HindmanDirector$212,723
• Mr. Robert MoreDirector, since 2013$139,219

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.